HRAS and cancer: Collectively, this evidence supports the idea that TRPML1 downregulation in HRAS-driven cancers diminished endo-lysosomal cholesterol trafficking to the plasma membrane, potentially impairing the recruitment and activation of oncogenic substrates within the MAPK pathway and negatively regulating cell proliferation [25].